Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer

Cell Death & Differentiation volume 30, pages 2213–2230 (2023)Cite this article

Subjects

Abstract

C-Myc overexpression contributes to multiple hallmarks of human cancer but directly targeting c-Myc is challenging. Identification of key factors involved in c-Myc dysregulation is of great significance to develop potential indirect targets for c-Myc. Herein, a collection of long non-coding RNAs (lncRNAs) interacted with c-Myc is detected in pancreatic ductal adenocarcinoma (PDAC) cells. Among them, lncRNA BCAN-AS1 is identified as the one with highest c-Myc binding enrichment. BCAN-AS1 was abnormally elevated in PDAC tumors and high BCAN-AS1 level was significantly associated with poor prognosis. Mechanistically, Smad nuclear-interacting protein 1 (SNIP1) was characterized as a new N6-methyladenosine (m6A) mediator binding to BCAN-AS1 via recognizing its m6A modification. m6A-modified BCAN-AS1 acts as a scaffold to facilitate the formation of a ternary complex together with c-Myc and SNIP1, thereby blocking S phase kinase-associated protein 2 (SKP2)-mediated c-Myc ubiquitination and degradation. Biologically, BCAN-AS1 promotes malignant phenotypes of PDAC in vitro and in vivo. Treatment of metastasis xenograft and patient-derived xenograft mouse models with in vivo-optimized antisense oligonucleotide of BCAN-AS1 effectively represses tumor growth and metastasis. These findings shed light on the pro-tumorigenic role of BCAN-AS1 and provide an innovant insight into c-Myc-interacted lncRNA in PDAC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: c-Myc associated lncRNA BCAN-AS1 is overexpressed in PDAC and associated with clinical outcomes in patients with PDAC.
Fig. 2: BCAN-AS1 promotes malignant phenotypes of PDAC in vitro and in vivo.
Fig. 3: BCAN-AS1 upregulates c-Myc targets to enhance malignant phenotypes of PDAC cells.
Fig. 4: BCAN-AS1 directly interacts with c-Myc and increases c-Myc protein expression in PDAC cells.
Fig. 5: BCAN-AS1 mediates increased binding of SNIP1 to c-Myc and prevents c-Myc degradation by SKP2.
Fig. 6: BCAN-AS1 recruits SNIP1 binding via its m6A modification.
Fig. 7: BCAN-AS1 is a therapeutic target in mouse PDAC xenografts.

Similar content being viewed by others

Data availability

C-Myc RIP-seq, RNA-seq and SNIP1 CLIP-seq raw data generated in this study are publicly available in the Gene Expression Omnibus at GSE181777. miCLIP sequencing data have been deposited in the NCBI Short Read Archive with the BioProject ID-PRJNA693621. All custom code used to generate the data in this study is available upon reasonable request.

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.

    Article  PubMed  Google Scholar 

  3. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024–1039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321–334.

    Article  CAS  PubMed  Google Scholar 

  5. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301–309.

    Article  PubMed  Google Scholar 

  6. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res. 2023;83:626–640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sodir NM, Pellegrinet L, Kortlever RM, Campos T, Kwon YW, Kim S, et al. Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution. Nat Commun. 2022;13:6782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211–1218.

    Article  CAS  PubMed  Google Scholar 

  10. Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with ras by programming inflammation and immune suppression. Cell. 2017;171:1301–1315.e1314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hessmann E, Schneider G, Ellenrieder V, Siveke JT. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene. 2016;35:1609–1618.

    Article  CAS  PubMed  Google Scholar 

  13. Skoudy A, Hernandez-Munoz I, Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. J Gastrointest Cancer. 2011;42:76–84.

    Article  CAS  PubMed  Google Scholar 

  14. Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, et al. MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 2020;10:588–607.

    Article  CAS  PubMed  Google Scholar 

  15. Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Saeid A, et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 2022;12:542–561.

    Article  CAS  PubMed  Google Scholar 

  16. Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371–377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, et al. Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. Cancer Discov. 2020;10:86–103.

    Article  CAS  PubMed  Google Scholar 

  18. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18:5546–5553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102–104.

    Article  CAS  PubMed  Google Scholar 

  20. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455:679–683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23–36.

    Article  CAS  PubMed  Google Scholar 

  23. Duffy MJ, Crown J. Drugging “undruggable” genes for cancer treatment: are we making progress? Int J Cancer. 2021;148:8–17.

    Article  CAS  PubMed  Google Scholar 

  24. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–159.

    Article  CAS  PubMed  Google Scholar 

  25. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–914.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62.

    Article  CAS  PubMed  Google Scholar 

  27. Huang H, Weng H, Chen J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–1261.

    Article  CAS  PubMed  Google Scholar 

  30. Iaccarino I. lncRNAs and MYC: an intricate relationship. Int J Mol Sci. 2017;18:1497.

  31. Swier L, Dzikiewicz-Krawczyk A, Winkle M, van den Berg A, Kluiver J. Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer. Mol Oncol. 2019;13:26–45.

    Article  CAS  PubMed  Google Scholar 

  32. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512:82–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33:706–720.e709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA. 2014;111:18697–18702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, et al. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018;37:6166–6179.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang Y, Gao L, Ma S, Ma J, Wang Y, Li S, et al. MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma. Cell Death Differ. 2019;26:2061–2073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, et al. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol. 2021;22:104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Shen S, Yao T, Xu Y, Zhang D, Fan S, Ma J. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 2020;19:151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Yang Q, Du WW, Wu N, Yang W, Awan FM, Fang L, et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 2017;24:1609–1620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12:433–446.

    Article  CAS  PubMed  Google Scholar 

  41. Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–5339.

    Article  PubMed  Google Scholar 

  42. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884–i890.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.

    Article  CAS  PubMed  Google Scholar 

  44. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.

    Article  CAS  Google Scholar 

  45. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–15550.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87.

    Article  CAS  PubMed  Google Scholar 

  48. Zhang J, Bai R, Li M, Ye H, Wu C, Wang C, et al. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019;10:1858.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Moore MJ, Zhang C, Gantman EC, Mele A, Darnell JC, Darnell RB. Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat Protoc. 2014;9:263–293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Shah A, Qian Y, Weyn-Vanhentenryck SM, Zhang C. CLIP Tool Kit (CTK): a flexible and robust pipeline to analyze CLIP sequencing data. Bioinformatics. 2017;33:566–567.

    Article  CAS  PubMed  Google Scholar 

  52. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015;12:767–772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Uren PJ, Bahrami-Samani E, Burns SC, Qiao M, Karginov FV, Hodges E, et al. Site identification in high-throughput RNA-protein interaction data. Bioinformatics. 2012;28:3013–3020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Robinson J, Thorvaldsdóttir H, Winckler W, Guttman M, Lander E, Getz G, et al. Integrated genomics viewer. Nat Biotechnol. 2011;29:24–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Wang L, Park HJ, Dasari S, Wang S, Kocher JP, Li W. CPAT: coding-potential assessment tool using an alignment-free logistic regression model. Nucleic Acids Res. 2013;41:e74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Deng J, Zhang J, Ye Y, Liu K, Zeng L, Huang J, et al. N6-methyladenosine-mediated upregulation of WTAPP1 promotes WTAP translation and wnt signaling to facilitate pancreatic cancer progression. Cancer Res. 2021;81:5268–5283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Muppirala UK, Honavar VG, Dobbs D. Predicting RNA-protein interactions using only sequence information. BMC Bioinforma. 2011;12:489.

    Article  CAS  Google Scholar 

  59. Farrell AS, Sears RC. MYC degradation. Cold Spring Harb Perspect Med. 2014;4:a014365.

  60. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell. 2003;11:1177–1188.

    Article  CAS  PubMed  Google Scholar 

  61. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–1200.

    Article  PubMed  Google Scholar 

  62. Fujii M, Lyakh LA, Bracken CP, Fukuoka J, Hayakawa M, Tsukiyama T, et al. SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes. Mol Cell. 2006;24:771–783.

    Article  CAS  PubMed  Google Scholar 

  63. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m6A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335–345.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69:1193–1205.

    Article  CAS  PubMed  Google Scholar 

  65. Li J, Chen Z, Chen F, Xie G, Ling Y, Peng Y, et al. Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res. 2020;48:5684–5694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Li Z, Peng Y, Li J, Chen Z, Chen F, Tu J, et al. N6-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat Commun. 2020;11:2578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Shao B, Fu X, Li X, Li Y, Gan N. RP11-284F21.9 promotes oral squamous cell carcinoma development via the miR-383-5p/MAL2 axis. J Oral Pathol Med. 2020;49:21–29.

    Article  CAS  PubMed  Google Scholar 

  68. Li D, Wang L, Feng J, Shen YW, Liu LN, Wang Y. RP11‑284F21.9 promotes lung carcinoma proliferation and invasion via the regulation of miR‑627‑3p/CCAR1. Oncol Rep. 2020;44:1638–1648.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Han HF, Chen Q, Zhao WW. Long non-coding RNA RP11-284F21.9 functions as a ceRNA regulating PPWD1 by competitively binding to miR-769-3p in cervical carcinoma. Biosci. Rep. 2020;40:BSR20200784.

  70. Roche KC, Wiechens N, Owen-Hughes T, Perkins ND. The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression. Oncogene. 2004;23:8185–8195.

    Article  CAS  PubMed  Google Scholar 

  71. Kim RH, Flanders KC, Birkey Reffey S, Anderson LA, Duckett CS, Perkins ND, et al. SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional co-activators. J Biol Chem. 2001;276:46297–46304.

    Article  CAS  PubMed  Google Scholar 

  72. Chen LL, Lin HP, Zhou WJ, He CX, Zhang ZY, Cheng ZL, et al. SNIP1 recruits TET2 to regulate c-MYC target genes and cellular DNA damage response. Cell Rep. 2018;25:1485–1500.e1484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–641.

    Article  CAS  PubMed  Google Scholar 

  74. Zhong Y, Yang L, Xiong F, He Y, Tang Y, Shi L, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther. 2021;6:240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404.

    Article  PubMed  Google Scholar 

  76. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Zhou KR, Liu S, Sun WJ, Zheng LL, Zhou H, Yang JH, et al. ChIPBase v2.0: decoding transcriptional regulatory networks of non-coding RNAs and protein-coding genes from ChIP-seq data. Nucleic Acids Res. 2017;45:D43–D50.

    Article  CAS  PubMed  Google Scholar 

  78. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–1200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Lee J, Wu Y, Harada BT, Li Y, Zhao J, He C et al. N6-methyladenosine modification of lncRNA Pvt1 governs epidermal stemness. EMBO J. 2021;40:e106276.

Download references

Acknowledgements

This study was supported by the National Key R&D Program of China (2021YFA1302100 to J. Zheng), National Natural Science Foundation of China (82325037, 82072617 to J. Zheng and 82003162 to J. Zhang), Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096 to D.L.), China Postdoctoral Science Foundation (2023M734042 to J.S.) and Sun Yat-sen University Intramural Funds (to D.L. and to J. Zheng).

Author information

Author notes

  1. These authors contributed equally: Guandi Wu, Jiachun Su, Lingxing Zeng, Shuang Deng.

Authors and Affiliations

  1. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

    Guandi Wu, Jiachun Su, Lingxing Zeng, Shuang Deng, Xudong Huang, Ying Ye, Rui Li, Ruihong Bai, Lisha Zhuang, Yanfen Zheng, Junge Deng, Shaoping Zhang, Dongxin Lin, Jialiang Zhang & Jian Zheng

  2. Department of Clinical Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    Jiachun Su

  3. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China

    Mei Li

  4. Department of Pancreaticobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    Quanbo Zhou

  5. Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

    Rufu Chen

  6. Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Dongxin Lin

  7. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China

    Dongxin Lin & Jian Zheng

Authors
  1. Guandi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiachun Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingxing Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xudong Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ying Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruihong Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lisha Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Quanbo Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yanfen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Junge Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shaoping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Rufu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Dongxin Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jialiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Jian Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J. Zheng and J. Zhang conceptualized and supervised this study. G.W., J.S. and L. Zeng performed most experiments. S.D., Y.Y. and R.L. conducted statistical and bioinformatics analyses. J. Zhang and X.H. performed animal experiments. Q.Z., Y.Z., J.D., S.Z. and R.C. contributed to collection of clinic samples. M.L. contributed to histopathological analyses. R.B. and L. Zhuang provided technique supports. G.W. J.S., J. Zheng and D.L. prepared manuscript. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Jialiang Zhang or Jian Zheng.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

This study was approved by the Institutional Review Board of the Sun Yat-sen Memorial Hospital and Chinese Academy of Medical Sciences Cancer Hospital. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Sun Yat-sen University Cancer Center and the animals were handled in accordance with institutional guidelines.

Informed consent

Informed consent was obtained from each patient.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, G., Su, J., Zeng, L. et al. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Cell Death Differ 30, 2213–2230 (2023). https://doi.org/10.1038/s41418-023-01225-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41418-023-01225-x

Search

Advanced search

Quick links